<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human leukocyte antigen-G (HLA-G) is a novel <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker and its soluble isoforms produce secretory proteins </plain></SENT>
<SENT sid="1" pm="."><plain>Increased soluble HLA-G (sHLA-G) levels have been reported in patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo>, <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>, <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, breast, ovarian and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> when compared to healthy controls or subjects with benign <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study is to investigate whether or not plasma sHLA-G can be used as a potential biomarker for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>We measured plasma sHLA-G levels in 166 patients with early stages of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, n = 37), <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> (GC, n = 28), esophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>, n = 58) and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>, n = 43), and compared them to healthy controls (n = 260) by using a specific HLA-G enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="4" pm="."><plain>We found that plasma sHLA-G levels were significantly higher in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients than in healthy controls (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>The areas under the receiver-operating characteristic (ROC) curves for sHLA-G were 0.97, 0.91, 0.98 and 0.80 for healthy controls vs <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, GC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>At 100% specificity, the highest sensitivity achieved to detect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, GC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> was 94% [95% confidence interval (CI), 89-99], 85% (95% CI, 76-94), 91% (95% CI, 88-94) and 51% (95% CI, 43-59) at a cutoff value of 49 U/ml, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that plasma sHLA-G may be a useful molecule in the differential diagnosis of these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> against healthy controls </plain></SENT>
</text></document>